Clinical Trial Update: Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial of allogeneic CD19/BCMA CAR-T therapy for B-cell–related autoimmune diseases is recruiting at The Children's Hospital of Zhejiang Universit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Iga Nephropathy
• Multidrug-resistant Nephrotic Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Allogeneic CD19/BCMA CAR-T (CD19/BCMA CAR-T cell therapy)

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | EARLY_Phase 1 | Status: RECRUITING